BIA
- Generic Name
- BIA
- Drug Type
- Small Molecule
- Chemical Formula
- C20H20F3N3O5
- Unique Ingredient Identifier
- X6H65DT067
Tolerability, Pharmacokinetics and Dopamine ß-hydroxylase (DßH) Inhibition Profile of BIA 5-453
Phase 1
Completed
- Conditions
- Chronic Heart FailureHypertension
- Interventions
- Drug: Placebo
- First Posted Date
- 2016-07-26
- Last Posted Date
- 2016-07-26
- Lead Sponsor
- Bial - Portela C S.A.
- Target Recruit Count
- 80
- Registration Number
- NCT02845037
- Locations
- 🇫🇷
Biotrial, Rennes, France
Tolerability, Pharmacokinetics and Pharmacodynamics of Six Multiple Rising Dose Regimens of BIA 5-453
Phase 1
Completed
- Conditions
- HypertensionChronic Heart Failure
- Interventions
- Drug: Placebo
- First Posted Date
- 2016-07-21
- Last Posted Date
- 2016-07-21
- Lead Sponsor
- Bial - Portela C S.A.
- Target Recruit Count
- 57
- Registration Number
- NCT02840565
Effect of Two Multiple-dose Regimens of BIA 3-202 on the Pharmacokinetics and Motor Response of Levodopa, and on the Erythrocyte Comt Activity in Parkinson's Disease Patients
Phase 2
Completed
- Conditions
- Parkinson's Disease (PD)
- Interventions
- First Posted Date
- 2016-07-15
- Last Posted Date
- 2016-07-15
- Lead Sponsor
- Bial - Portela C S.A.
- Target Recruit Count
- 19
- Registration Number
- NCT02834507
Pharmacokinetic-pharmacodynamic Interaction Between BIA 3-202 and Levodopa/Benserazide
Phase 1
Completed
- Conditions
- Parkinson's Disease (PD)
- Interventions
- First Posted Date
- 2016-05-20
- Last Posted Date
- 2016-06-14
- Lead Sponsor
- Bial - Portela C S.A.
- Target Recruit Count
- 17
- Registration Number
- NCT02778594
- Locations
- 🇵🇹
Human Pharmacology Unit, S. Mamede do Coronado, Portugal
Effect of BIA 3-202 on the Pharmacokinetics and Pharmacodynamics of Warfarin
- First Posted Date
- 2016-05-20
- Last Posted Date
- 2017-08-24
- Lead Sponsor
- Bial - Portela C S.A.
- Target Recruit Count
- 16
- Registration Number
- NCT02779348
- Locations
- 🇵🇹
Human Pharmacology Unit (UFH),, S. Mamede do Coronado, Portugal
Effect of Eslicarbazepine Acetate on the Pharmacokinetics of Gliclazide in Healthy Volunteers
- First Posted Date
- 2016-05-19
- Last Posted Date
- 2016-05-19
- Lead Sponsor
- Bial - Portela C S.A.
- Target Recruit Count
- 20
- Registration Number
- NCT02777671
- Locations
- 🇵🇹
Human Pharmacology Unit, S. Mamede do Coronado, Portugal
Pharmacokinetic-pharmacodynamic Interaction Between BIA 3-202 and Levodopa/Carbidopa
Phase 1
Completed
- Conditions
- Parkinson's Disease
- Interventions
- First Posted Date
- 2016-05-17
- Last Posted Date
- 2016-05-19
- Lead Sponsor
- Bial - Portela C S.A.
- Target Recruit Count
- 16
- Registration Number
- NCT02774564
- Locations
- 🇵🇹
Human Pharmacology Unit, S. Mamede do Coronado, Portugal
Absorption, Distribution, Metabolism and Excretion of [14C]-Labelled BIA 3-202 and Metabolites
- First Posted Date
- 2016-05-13
- Last Posted Date
- 2016-05-13
- Lead Sponsor
- Bial - Portela C S.A.
- Target Recruit Count
- 4
- Registration Number
- NCT02772614
- Locations
- 🇨🇭
Swiss Pharma Contract Ltd, Allschwil, Basel, Switzerland
Pharmacokinetic-Pharmacodynamic Interaction Between Four Different Single Doses of BIA 3-202 and a Single Dose of Levodopa/Benserazide (100/25 mg)
Phase 1
Completed
- Conditions
- Parkinson's Disease
- Interventions
- First Posted Date
- 2016-05-05
- Last Posted Date
- 2016-05-05
- Lead Sponsor
- Bial - Portela C S.A.
- Target Recruit Count
- 18
- Registration Number
- NCT02763852
- Locations
- 🇵🇹
Human Pharmacology Unit - BIAL - Portela & Ca, S.A., S. Mamede do Coronado, Portugal
Pharmacokinetic-Pharmacodynamic Interaction Between Four Different Single Doses of BIA 3-202 and a Single Dose of Levodopa/Carbidopa (100/25 mg)
Phase 1
Completed
- Conditions
- Parkinson's Disease
- Interventions
- First Posted Date
- 2016-05-05
- Last Posted Date
- 2016-05-05
- Lead Sponsor
- Bial - Portela C S.A.
- Target Recruit Count
- 19
- Registration Number
- NCT02763839
- Locations
- 🇵🇹
Human Pharmacology Unit - BIAL - Portela & Ca, S.A., S. Mamede do Coronado, Portugal
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath